$Longeveron (LGVN.US)$
Earnings report in 2 days.  😲

$Longeveron (LGVN.US)$
On its way today
Pain staking searches will always produce results. Patience is a virtue
1. My strategy is to find an item that has immediate results in order to sell and recuperate the initial investment by selling 50% of the initial shares purchased. (SureBet!)
2. Leaving the remaining 50% to hit as a limit sale at the obnoxious goal minus 20% for a safer bet. (Long-TermSpecial)
The Father of Stocks: Laying the groundwork for market an...

$Longeveron (LGVN.US)$
$Longeveron (LGVN.US)$ is scheduled to release its financial results post-market on February 28 ET.
EPS is estimated to be USD-0.36, Net Loss Narrowed 85.74% YoY.

Today's Top early risers!
$Neumora Therapeutics (NMRA.US)$
$Longeveron (LGVN.US)$
$Ocean Biomedical (OCEA.US)$
$Zomedica (ZOM.US)$
TheFather's portfolio up a total of 3% early this morning
Take your profits. Good luck, everyone!

$Longeveron (LGVN.US)$ $Neumora Therapeutics (NMRA.US)$
My two additions for my strategy
Pain staking searches will always produce results. 
1. My strategy is to find an item that has immediate results in order to sell and recuperate the initial investment by selling 50% of the initial shares purchased. (SureBet!)
2. Leaving the remaining 50% to hit as a limit sale at the obnoxious goal minus 20% for a safer bet. (Long-TermSpecial)
The Father of Stocks: Laying...

$Longeveron (LGVN.US)$
The WHO's approval of 'laromestrocel' as the International Non-proprietary Name for Lomecel-B™ marks a important advancement in Longeveron's commercialization strategy. This milestone carries significant implications beyond mere nomenclature - it represents international recognition and standardization of the therapy's identity, facilitating global regulatory processes and market access preparations.
The dual-indication strategy targeting both Alzh...

$Longeveron (LGVN.US)$ last minute news maybe a runner

$Longeveron (LGVN.US)$
Breakthrough Alzheimer's Treatment Gets Official WHO Recognition - Major Milestone for Rare Disease Therapy

$Longeveron (LGVN.US)$
Longeveron® Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
Tuesday, 18th February at 9:25 am
Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of "laromestrocel" on the INN List issued by the World Health Organization (WHO)
Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer's disease and hypoplastic ...